Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Family Medicine
 Disease Category: Cancer Treatment
Location: United States, CA

Trial Information

PHI-66 NCI#8846- Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients with Varying Degrees of Hepatic Dysfunction

You have been asked to participate in this research study because you have an advanced cancer, your liver may or may not be working properly, and the standard drugs to treat your disease are no longer effective or there is no known effective treatment for your disease. The purpose of this study is to test the safety of belinostat at different dose levels in research participants with cancer who have different degrees of liver function, including research participants with normal liver function. Other purposes of this study are to find out what side effects occur when belinostat is given to research participants with different degrees of liver function, how much belinostat stays in the blood at specific times, and whether or not belinostat is effective in treating cancer in research participants with different degrees of liver function. Your treatment on this study is expected to last as long as your tumor is not growing and you are not experiencing any unmanageable side effects.After your treatment on this study is over, your medical condition will continue to be followed indefinitely.

Patient Inclusion/Exclusion Criteria:


- See http://clinicaltrials.coh.org for additional information.


City of Hope
1500 East Duarte Road
Duarte, CA 91010-3000
Phone: 866-896-HOPE (4673)

View Map

Research Center Information: City of Hope

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.